CATEGORIES

  • Acupuncture
  • Allied
  • Alternative Health
  • Ambulance Services
  • Anaesthetists
  • Animal Health
  • Aquatic Therapist
  • Aromatherapy
  • Audiometric
  • Ayurveda Practitioner
  • Biokineticist
  • Cardiac & Thoracic Surgeon
  • Cardiologists
  • Chiropractors
  • General Clinics
  • Government Clinics
  • Private Clinics
  • Specialist
  • Dental Surgeons
  • Dentist
  • Dermatologists
  • Dieticians
  • Ear Nose & Throat Surgeons
  • Emergency Medicines
  • Emergency Services
  • Gastroenterologists
  • General Practitioner
  • Gynaecologist
  • Health & Beauty
  • Health Insurance
  • Healthcare Suppliers
  • Hearing Aids
  • HIV/AIDS
  • Homeopaths
  • Hospital & Clinic Groups
  • Hospitals
  • Hospital Specialist
  • Managed Health Care
  • Massage Therapists
  • Medical Aid Schemes
  • Medical Practitioners
  • Medical Publishers
  • Medical Scientists
  • Medical Suppliers
  • Medical Technicians
  • Microbiology
  • Naturopaths
  • Nephrologists
  • Neurologist
  • Neurosurgeons
  • Nuclear Medicine
  • Nurses
  • Occupational Health
  • Occupational Medicine
  • Occupational Therapists
  • Oncology
  • Ophthalmology
  • Optometrists
  • Oral Hygiene
  • Orthodontics
  • Orthopedic
  • Orthotics & Prosthetics
  • Osteopaths
  • Pathologists
  • Pediatricians
  • Pediatrics
  • Periodontics
  • Personal Trainers
  • Pharmaceutical Manufacturers
  • Pharmaceutical Suppliers
  • Pharmacies - Retails
  • Pharmacies - Wholesale
  • Pharmacologists
  • Pharmacotherapy
  • Pharmacy Clinics
  • Pharmacy Groups
  • Physicians
  • Physiotherapy
  • Plastic Surgeons
  • Podiatrists
  • Prosthodontics
  • Psychiatry
  • Psychology
  • Psychometrics
  • Pulmonologists
  • Radiographers
  • Radiologists
  • Radiotherapists
  • Recruitment
  • Reflexology
  • Reproductive Medicine
  • Sexologists
  • Sexuality
  • Social Services
  • Speech
  • Sports Medicine
  • Surgeons
  • Training Institutions
  • Urologists
  • Vascular Surgeons
  • Veterinary Clinics
  • Veterinary surgeons
  • Other
  • Medical Finance
  • Renewable Energy & Back Up Power
  • Auxiliary Services
  • Pest Control
  • Allergies



  • Upcoming Events

    The South African Pharmaceutical Exhibition (SAPHEX) is scheduled for March 5-6, 2025, at the Sandton Convention Centre in Johannesburg.

    SAPHEX stands as the premier event for professionals in South Africa's pharmaceutical manufacturing industry. The exhibition brings together key players, decision-makers, and suppliers, showcasing the latest innovations in APIs, excipients, packaging, and machinery. Attendees can expect to network, explore new advancements, and engage in discussions pivotal to the growth of the African pharmaceutical market.


    Share this article

    Favorite this

    856

    Registration Details

    Visit Website

    Latest Medical Articles

    Unusual bleeding during and after pregnancy

    When should pregnant women be concerned? Awareness of the dangers associated with abnormal bleeding during pregnancy and after childbirth can be lifesaving for both women and their babies.

    Dr. Mzuvele Archwell Hlabisa, an obstetrician and gynaecologist at Netcare Kingsway Hospital, emphasizes that while many people are unaware that over a third of pregnant women may experience bleeding for various reasons, it is crucial to determine the exact cause.

    "Although some bleeding is normal in the postpartum period, excessive bleeding can be life-threatening. It is often difficult for women to discern if their bleeding is normal or not, but a good rule of thumb is to have any bleeding during pregnancy checked by a healthcare professional," says Dr. Hlabisa.

    He notes that around 35% of women experience bleeding in the first trimester. "As the pregnancy progresses, the likelihood of bleeding decreases, so it’s reassuring when women reach the mid-trimester, from 13 to 28 weeks of gestation."

    Bleeding could indicate a miscarriage or a threatened miscarriage, and severe pain with bleeding could be related to placental abruption, a serious condition where the placenta prematurely separates from the womb. These conditions require immediate medical assessment.

    Spotting In early pregnancy, some women may experience spotting, known as implantation bleeding, when the embryo implants in the uterine wall. ...Read full article

    Share this article

    Sponsored by:

    Netcare Hospitals

    Favorite this

    2.1k
    VIEW ALL ARTICLES

    Global Medical News

    Dark Chocolate May Slow Ageing and Improve Health Markers
    A Sweet Discovery from Everyday Foods

    A new study from King’s College London suggests that a key compound found in dark chocolate - theobromine - may be linked to slower biological ageing in humans. Rather than measuring age by years lived, researchers looked at biological age, a marker of how well the body is functioning at the molecular level in comparison to chronological age. This study, published today in the journal Aging, analyzed data from more than 1,600 adults and found that individuals with higher levels of theobromine in their blood tended to have a younger biological profile

    How theobromine May Influence Ageing

    Rather than simply focusing on diet or calendar age, the study measured DNA methylation - small chemical tags on DNA that change predictably with age - and related those patterns to theobromine levels in participants’ blood. Those with higher theobromine levels generally showed patterns associated with younger biological age, and in some cases longer protective telomere length, a separate molecular marker tied to cellular ageing.

    Theobromine is a natural plant compound found in cocoa beans, and it’s much more abundant in dark chocolate than in milk chocolate. It belongs to a class of chemicals called methylxanthines, which also includes caffeine, though theobromine acts differently in the body.

    Potential Health Benefits and Caution

    While these findings are exciting and suggest that components of dark chocolate might offer clues to healthier ageing, scientists are clear that this research does not prove that eating more dark chocolate will slow ageing. The study shows a correlation between higher circulating theobromine and biological age markers, but it cannot yet confirm cause and effect, nor that theobromine alone is responsible - other compounds in chocolate like polyphenols may also play a role.

    Moreover, chocolate also contains sugar and fat, so increasing consumption solely for anti-ageing purposes isn’t advised. Instead, researchers say the results help point toward how everyday foods contain molecular clues that may inform long-term health and longevity research.
    11 December 2025

    Scientists Say Experimental Drug May Solve Common Issues Patients Have on Metabolic drugs
    New Hope for Muscle Preservation During Weight Loss

    Researchers have unveiled a promising new oral medication, ATR-258, that could address one of the most persistent drawbacks of popular GLP-1 receptor agonist therapies - the unintended loss of muscle mass that often accompanies weight loss. GLP-1 drugs like Ozempic and Wegovy have revolutionized treatment for obesity and type 2 diabetes by suppressing appetite and improving glucose control, but many patients experience loss of both fat and muscle, potentially leading to frailty, slower metabolism, and long-term health concerns.

    ATR-258 is a beta-2 adrenergic agonist, a class of compounds that includes well-known medications such as ibuterol. Unlike GLP-1 therapies that primarily act on gut-brain signals to reduce hunger, ATR-258 works directly on muscle-related signalling pathways to boost glucose uptake, enhance fat burning, and support muscle maintenance during weight loss. Early research characterizes its effect as sounding like “exercise in a pill,” because it activates molecular pathways in skeletal muscle that promote strength and metabolic activity without significantly overstimulating the heart.

    Early Results from Studies

    In laboratory and early human testing, ATR-258 has shown positive signs of safety and tolerability. Animal studies reported improved blood sugar regulation and enhanced muscle preservation, while a small phase 1 clinical trial involving both healthy volunteers and individuals with type 2 diabetes found the drug was generally well-tolerated. Some mild side effects, such as hand tremors and short-lived increases in heart rate, were observed, but no serious adverse events emerged.

    This contrasts with typical GLP-1 side effects, which often include gastrointestinal symptoms like nausea, vomiting, and diarrhoea - common challenges that lead some patients to discontinue therapy.

    Why This Matters

    Maintaining muscle mass during weight loss is important for long-term health, especially as muscle plays a crucial role in metabolism, strength, balance, and overall quality of life. Losing too much muscle can slow metabolic rate, increase fatigue, and potentially raise the risk of other health issues. ATR-258’s approach - focusing on preserving lean muscle while supporting fat reduction - could complement existing treatments and expand options for people managing obesity or metabolic disease.

    Next Steps in Development

    Though the early results are encouraging, ATR-258 is still in the early stages of research. Larger and longer clinical trials will be required to confirm its safety and effectiveness and to determine whether it can be approved for widespread clinical use. Researchers are optimistic that continued development will clarify the drug’s potential role alongside or as an alternative to current GLP-1 therapies.
    11 December 2025

    Betel Leaves Show Potential in Alzheimer’s Research
    A Traditional Plant in a New Scientific Spotlight

    Betel leaves, known locally as paan and traditionally valued across South Asia for their antioxidant and anti-inflammatory properties, are now attracting scientific attention for their potential role in addressing Alzheimer’s disease - a debilitating and currently incurable neurodegenerative disorder. Researchers have begun exploring how specific compounds in Piper betel might interact with biological pathways involved in Alzheimer’s, offering clues that could help guide future therapy development.

    Investigating Hydroxychavicol and Brain Targets

    The most promising compound identified in betel leaves is hydroxychavicol, a naturally occurring phenolic molecule with known antioxidant activity. Using computer-based techniques such as molecular docking and network pharmacology, scientists mapped how hydroxychavicol might bind to proteins implicated in Alzheimer’s pathology - including targets involved in neurotransmitter regulation, oxidative stress, inflammation, and key cell signalling pathways. These in silico findings suggest the compound could modulate multiple disease-relevant mechanisms simultaneously, an encouraging sign for further study.

    What This Could Mean for Alzheimer’s Research

    Alzheimer’s disease affects millions worldwide, leading to progressive memory loss, cognitive decline, and behavioural changes without any disease-modifying treatments currently available. While these new results are preliminary and largely computational, they provide a scientific rationale for deeper biological testing. Betel leaf compounds like hydroxychavicol - if future lab, animal, and clinical studies confirm safety and effectiveness - might contribute to the development of novel treatment approaches that target the disease’s complex biology.

    Next Steps and Cautions

    Experts note that although these early findings are intriguing, hydroxychavicol’s potential must be validated in laboratory experiments and eventually human clinical trials before any conclusions can be drawn about therapeutic use. Alzheimer’s research has historically seen promising leads fail to translate into effective treatments, so cautious optimism is advised. Nonetheless, this investigation underscores how traditional medicinal plants continue to inspire modern drug discovery efforts.
    11 December 2025

    New Research Suggests Diet and Exercise Could Reduce Chemo Side Effects
    Lifestyle Support During Treatment

    Cancer treatment - especially chemotherapy - often brings a range of debilitating side effects, from fatigue and pain to anxiety and depression. Early findings from the LIFE-L study, presented at the 2025 American Society of Haematology conference, suggest that integrating diet and exercise support delivered virtually can help patients better tolerate therapy and feel stronger during the course of their treatment.

    What the Study Did

    The research, led by a team at the Sylvester Comprehensive Cancer Centre, enrolled lymphoma patients undergoing standard chemotherapy and offered a virtual diet and fitness program to a portion of participants. The intervention included weekly online sessions with registered dietitians and exercise physiologists tailored to each patient’s needs while they continued their prescribed chemotherapy regimen.

    Encouraging Early Results

    Participants in the lifestyle program reported fewer negative symptoms compared with those who did not receive the intervention. They experienced lower rates of anxiety, depression, fatigue, pain, and constipation, and also showed greater physical strength and performance in simple fitness tests. Attendance was high, indicating patients were both willing and able to engage with the virtual coaching during treatment.

    Why This Matters

    Completing the full course of chemotherapy without interruption is critical for the best outcomes, but side effects often force dose reductions or delays. Improving patients’ overall well-being, strength, and symptom burden through diet and exercise could help more individuals stay on track with therapy and potentially improve long-term results. The LIFE-L study underscores a broader movement in oncology toward integrating lifestyle support directly into treatment care - not just before or after chemotherapy, but during it.
    11 December 2025

    Long COVID Research Gets a Major Funding Boost
    A Major National Investment in Post-Infection Science

    In a major effort to deepen understanding of long COVID and related post-infection syndromes, the government of Germany has pledged €500 million (about US $580 million) to support research over the next decade. This funding will launch a National Decade Against Post-Infectious Diseases, spanning 2026 to 2036, with the goal of improving knowledge of conditions such as long COVID and chronic fatigue syndrome (also called ME/CFS), and accelerating the discovery of effective treatments.

    Why It Matters

    Long COVID has been widely recognized as a persistent and complex condition, where symptoms such as fatigue, cognitive impairment, and other multi-system issues can linger months or years after the initial SARS-CoV-2 infection. Similar post-infection syndromes, like ME/CFS, have historically received limited funding and scientific attention despite their significant impact on patients’ lives. The new investment aims to change that by providing stable, long-term support for research into the causes, mechanisms, diagnostics, and potential therapies for these conditions.

    Focus on Science, Collaboration, and Innovation

    Under the decade-long initiative, funds will be distributed to research institutions across Germany and potentially foster international collaboration. The aims include expanding clinical trials, improving biomarker and diagnostic research, supporting junior scientists entering the field, and enhancing understanding of both long COVID’s biological underpinnings and its overlap with other post-infection conditions. This comprehensive approach intends to build a stronger scientific infrastructure for tackling a class of diseases that have long been challenging to define and treat.

    A Step Toward Better Care and Treatment

    While the scientific community continues to make incremental advances in understanding long COVID, this substantial, strategic funding commitment reflects the urgency and importance of the issue both in Germany and globally. By investing in robust research and fostering interdisciplinary collaboration, health experts hope to uncover new therapeutic options, refine care strategies for affected patients, and potentially alleviate the long-term health burden of post-infection syndromes.
    11 December 2025

    LSU Researcher Invents New Ball Game Device to Transform Public Health Testing
    Innovative Tool for Rural Public Health

    In a move that could transform public health monitoring in small towns and rural areas, a Louisiana State University engineering professor has developed a simple yet powerful device that makes wastewater testing far more accessible and affordable. Aaron Bivins, an assistant professor in LSU’s Civil and Environmental Engineering Department, teamed up with his students to design a low-cost wastewater sampler that costs about $4 to make using a 3-D printer and basic materials.

    How It Works

    The device resembles a perforated plastic ball and houses a packet of activated charcoal. Researchers attach it to a string and lower it into sewage or wastewater, where it passively collects microbes and viral particles over time. Once retrieved, the collected material can be analysed to reveal what pathogens are present in the community’s wastewater stream. This technique allows detection of germs - including viruses and bacteria - similar to far more expensive automatic samplers that can cost $10,000 to $25,000, giving smaller communities an affordable alternative.

    Addressing Gaps in Surveillance

    Traditional wastewater surveillance systems focus mainly on large urban centres because they have the resources to install and power costly automatic samplers. Rural and under-resourced areas are often excluded, meaning outbreaks or infectious disease trends can go unnoticed. Bivins’s low-cost sampler can help fill this gap, enabling local officials and researchers alike to monitor disease spread more closely and in places that lacked such capability before.

    Published Findings and Future Impact

    Bivins and his team tested the device over a period of three months at a small wastewater treatment plant in Louisiana. Their results - which have been published in the academic journal Water Research - showed that the sampler can successfully capture microbial genetic material, offering valuable data for public health research and surveillance. The development has potential not just for traditional wastewater monitoring but also as a model for low-cost public health tools where resources are limited.
    11 December 2025
    VIEW ALL NEWS


    THE SPOTLIGHT



    Advancements in Cancer Treatment: Innovations and Breakthrough
    2024-07-15

    Celebrating 100 Years of Peel's: A Century of Pure Honey Excellence
    2024-05-30

    Premier Verification
    2023-02-08

    Tax Shop
    2023-02-07

    Medrisk
    2022-10-20

    A Complete End-To-End Solution for Healthcare Professionals
    2021-06-24


    Medical Videos




    Copyright © 2025 Dotcom Africa. All Rights Reserved. Advertising Terms | Terms of Use | Contact | Advertise with us | About Us